Suzetrigine: A New and Novel Analgesic for Acute Pain
Abstract
OBJECTIVES
Suzetrigine (Journavx), from a new class of non-opioid analgesics, is the first approved agent indicated for adults with moderate to severe pain in almost 3 decades. Reviewed are the drug's unique pharmacology, history of development, clinical evidence of safety and effectiveness, with an emphasis on implications for nursing practice. Literature describing the basic pharmacology as well as the results from extant clinical trials are integrated in this narrative educational review.
FINDINGS
Suzetrigine provides analgesia by blocking a specific sodium channel on peripheral nociceptors, interrupting pain signal transmission before reaching the central nervous system. In the clinical trials underlying Food and Drug Administration approval, 50 mg of suzetrigine (following a 100 mg loading dose) was demonstrated to be as effective as 5/325 mg hydrocodone/acetaminophen in patients undergoing bunionectomy or abdominoplasty and better tolerated. In subsequent open-label studies, 83%-91% of patients with diverse surgical and non-surgical conditions who received suzetrigine for up to 14 days rated analgesia as good to excellent, with few requiring rescue opioids. Currently, suzetrigine is approved only for acute pain, with ongoing trials evaluating its use for chronic pain conditions.
NURSING PRACTICE IMPLICATIONS
Concomitant medications must be carefully assessed as CPY3A inhibitors or inducers can change dosing requirements or even contraindicate use. The medication must…
Read the paper
Related studies
- Characterization and Analysis of Porosity and Pore Structures
- Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?
- Dental Optical Coherence Tomography
- Radiation-shielding concrete: A review of materials, performance, and the impact of radiation on concrete properties
- Testing entanglement of annihilation photons
- Calanus finmarchicus seasonal cycle and diapause in relation to gene expression, physiology, and endogenous clocks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.